Development and deployment of COVID-19 vaccines for those most vulnerable
暂无分享,去创建一个
R. Baric | G. Neumann | Y. Kawaoka | W. Koff | M. Cameron | A. McDermott | M. Osterholm | S. Schultz-Cherry | T. Ross | J. Goudsmit | T. Mastro | F. Priddy | Theodore Schenkelberg | K. Moore | C. Cameron | J. Ostrowsky | Tere M. Williams | A. Kelvin | M. Friemann | S. Schultz‐Cherry
[1] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[2] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[3] D. Lauffenburger,et al. Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[4] J. Mascola,et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.
[5] J. Bloom,et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2020, bioRxiv.
[6] Jon Cohen. ‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19 , 2020 .
[7] Nguyen H. Tran,et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.
[8] K. Chu,et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial , 2020, The Lancet Infectious Diseases.
[9] P. Kremsner,et al. Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers , 2020, medRxiv.
[10] Marc‐André D'Aoust,et al. Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants , 2020, medRxiv.
[11] M. Beltramello,et al. The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity , 2020, bioRxiv.
[12] C. Cordon-Cardo,et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.
[13] M. Lipsitch,et al. Understanding COVID-19 vaccine efficacy , 2020, Science.
[14] P. Doshi. Covid-19 vaccine trial protocols released , 2020, BMJ.
[15] B. Haynes,et al. Prospects for a safe COVID-19 vaccine , 2020, Science Translational Medicine.
[16] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[17] C. Franceschi,et al. Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population , 2020, Seminars in Immunopathology.
[18] J. Nkengasong,et al. COVID-19 vaccines: how to ensure Africa has access , 2020, Nature.
[19] V. Gladyshev,et al. COVID‐19 is an emergent disease of aging , 2020, Aging cell.
[20] R. Baric,et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.
[21] N. Hacohen,et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity , 2020, Science.
[22] Steven M. Holland,et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.
[23] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.
[24] F. Krammer. SARS-CoV-2 vaccines in development , 2020, Nature.
[25] Lisa E. Gralinski,et al. Animal models for COVID-19 , 2020, Nature.
[26] D. Cummings,et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity , 2020, Nature Communications.
[27] M. Beltramello,et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.
[28] J. Cramer,et al. Evolution of the COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.
[29] A. Gintsburg,et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia , 2020, The Lancet.
[30] V. Shinde,et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.
[31] Lisa E. Gralinski,et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures , 2020, Nature.
[32] Yongli Yang,et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. , 2020, JAMA.
[33] Madeleine K. D. Scott,et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.
[34] J. Diedrich,et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate , 2020, bioRxiv.
[35] J. Scott,et al. Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors , 2020, Science.
[36] U. Reimer,et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.
[37] D. Weissman,et al. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization , 2020, Cell Host & Microbe.
[38] C. Rice,et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.
[39] Y. Hu,et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial , 2020, The Lancet.
[40] D. Gilroy,et al. Aging immunity may exacerbate COVID-19 , 2020, Science.
[41] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[42] Chuan Qin,et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques , 2020, Science.
[43] S. Rowland-Jones,et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.
[44] Anne M Johnson,et al. Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data , 2020, Wellcome open research.
[45] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[46] B. Coller,et al. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens , 2020, npj Vaccines.
[47] B. Drolet,et al. Multivalue ethical framework for fair global allocation of a COVID-19 vaccine , 2020, Journal of Medical Ethics.
[48] J. Singh. The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials , 2020, The Journal of infectious diseases.
[49] W. Koff,et al. The future of vaccine development. , 2020, Vaccine.
[50] Ilya J. Finkelstein,et al. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.
[51] Vineet D. Menachery,et al. The search for a COVID-19 animal model , 2020, Science.
[52] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[53] R. Baric,et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.
[54] P. Sorger,et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques , 2020, Science.
[55] X. Xie,et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.
[56] Jon Cohen. U.S. 'Warp Speed' vaccine effort comes out of the shadows. , 2020, Science.
[57] Christopher Earl,et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.
[58] D. Burton,et al. Rational Vaccine Design in the Time of COVID-19 , 2020, Cell Host & Microbe.
[59] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[60] John R. Mascola,et al. A strategic approach to COVID-19 vaccine R&D , 2020, Science.
[61] H. Yen,et al. Peer Review File Manuscript Title: Pathogenesis and transmission of SARS-CoV-2 in golden Syrian hamsters , 2020 .
[62] Barney S. Graham,et al. Rapid COVID-19 vaccine development , 2020, Science.
[63] C. Verschoor,et al. The immune response to influenza in older humans: beyond immune senescence , 2020, Immunity & Ageing.
[64] M. Hamburg,et al. The Equitable Distribution of COVID-19 Therapeutics and Vaccines. , 2020, JAMA.
[65] Anne M Johnson,et al. Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. , 2020, Wellcome open research.
[66] K. Neuzil,et al. Which Countries Have Adult Vaccine Programs? A Global Review of National Adult Influenza and Pneumococcal Vaccine Policies , 2020 .
[67] John K Billington,et al. Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks , 2020, Health Security.
[68] Koichi Yuki,et al. COVID-19 pathophysiology: A review , 2020, Clinical Immunology.
[69] W. Koff,et al. Covid-19 and Immunity in Aging Populations - A New Research Agenda. , 2020, The New England journal of medicine.
[70] T. Kuiken,et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model , 2020, Science.
[71] W. Wei,et al. Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[72] A. Zemla,et al. Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing , 2020, bioRxiv.
[73] Xuetao Cao. COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.
[74] Baoying Huang,et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 , 2020, Science.
[75] W. Koff,et al. Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome? , 2020, Trends in Immunology.
[76] Eun-Ha Kim,et al. Infection and Rapid Transmission of SARS-CoV-2 in Ferrets , 2020, Cell Host & Microbe.
[77] J. Wu,et al. Vaccine confidence in the time of COVID-19 , 2020, European Journal of Epidemiology.
[78] Y. Wen,et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.
[79] S. Berkley. COVID-19 needs a big science approach , 2020, Science.
[80] Wenling Wang,et al. Age‐related rhesus macaque models of COVID‐19 , 2020, Animal models and experimental medicine.
[81] Tao Zhang,et al. Pangolin homology associated with 2019-nCoV , 2020, bioRxiv.
[82] Wenling Wang,et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.
[83] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[84] E. Arias,et al. Mortality in the United States, 2018. , 2020, NCHS data brief.
[85] S. Oh,et al. Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity , 2019, Immune network.
[86] Phillip M. Muthoka,et al. The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships , 2019, Vaccine.
[87] R. Rappuoli,et al. Vaccines and global health: In search of a sustainable model for vaccine development and delivery , 2019, Science Translational Medicine.
[88] H. Woodrow,et al. : A Review of the , 2018 .
[89] M. Beibel,et al. TORC1 inhibition enhances immune function and reduces infections in the elderly , 2018, Science Translational Medicine.
[90] F. Brombacher,et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model , 2018, PLoS pathogens.
[91] A. Chit,et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis , 2018, Expert review of vaccines.
[92] B. Weinberger. Vaccines for the elderly: current use and future challenges , 2018, Immunity & Ageing.
[93] N. Grassly,et al. Causes of impaired oral vaccine efficacy in developing countries , 2017, Future microbiology.
[94] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[95] R. Kennedy,et al. Personalized vaccinology: A review , 2017, Vaccine.
[96] S. Plotkin,et al. The complexity and cost of vaccine manufacturing – An overview , 2017, Vaccine.
[97] G. Kobinger,et al. Syrian Hamsters as a Small Animal Model for Emerging Infectious Diseases: Advances in Immunologic Methods , 2016, Advances in experimental medicine and biology.
[98] J. Yewdell,et al. Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. , 2016, The Journal of infectious diseases.
[99] A. Ls,et al. Unmet need for contraception in developing countries: Examining womens reasons for not using a method. , 2016 .
[100] A. Pera,et al. Immunosenescence: Implications for response to infection and vaccination in older people. , 2015, Maturitas.
[101] K. Subbarao,et al. Animal models for SARS and MERS coronaviruses , 2015, Current Opinion in Virology.
[102] G. Kang,et al. Biological challenges to effective vaccines in the developing world , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[103] G. Alter,et al. Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. , 2015, Vaccine.
[104] John Earl,et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. , 2014, The New England journal of medicine.
[105] J. Singer,et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. , 2014, The Journal of clinical investigation.
[106] M. Elizabeth Halloran,et al. Optimal Vaccine Allocation for the Early Mitigation of Pandemic Influenza , 2013, PLoS Comput. Biol..
[107] Stephen S. H. Huang,et al. Differential Pathological and Immune Responses in Newly Weaned Ferrets Are Associated with a Mild Clinical Outcome of Pandemic 2009 H1N1 Infection , 2012, Journal of Virology.
[108] R. Baric,et al. Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease , 2011, Journal of Virology.
[109] J. Yewdell,et al. MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines , 2011, Science Translational Medicine.
[110] David P. Fidler,et al. Negotiating Equitable Access to Influenza Vaccines: Global Health Diplomacy and the Controversies Surrounding Avian Influenza H5N1 and Pandemic Influenza H1N1 , 2010, PLoS medicine.
[111] Tadataka Yamada. Poverty, wealth, and access to pandemic influenza vaccines. , 2009, The New England journal of medicine.
[112] Andrew Pekosz,et al. An immunosuppressed Syrian golden hamster model for SARS-CoV infection , 2008, Virology.
[113] D. Weiskopf,et al. Biology of immune responses to vaccines in elderly persons. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[114] B. Ni,et al. Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters. , 2007, Viral immunology.
[115] David K. Meyerholz,et al. Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.
[116] T. Slezak,et al. Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome , 2006, PLoS medicine.
[117] T. Greenough,et al. Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters , 2006, The Journal of infectious diseases.
[118] Cécile Viboud,et al. Antibody response to influenza vaccination in the elderly: a quantitative review. , 2006, Vaccine.
[119] B. Murphy,et al. Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters , 2005, Journal of Virology.
[120] L. Simonsen,et al. The Japanese experience with vaccinating schoolchildren against influenza. , 2001, The New England journal of medicine.
[121] A. Mccarthy. Development , 1996, Current Opinion in Neurobiology.
[122] D. Tyrrell,et al. The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.
[123] L. Wilkinson. Immunity , 1891, The Lancet.
[124] Ping Li,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .
[125] Daniel Coppard,et al. Quantitative Review , 2020, Encyclopedia of Personality and Individual Differences.
[126] J. Zimmermann. Manufacturing: An Overview , 2010 .
[127] S. Tyring,et al. Vaccine immunology , 2009, Dermatologic therapy.
[128] J. Cattell. The Future of , 1961 .